Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity

Metabolism: Clinical and Experimental

Volumn 58, Issue 10, 2009, Pages 1430-1438

  Kristensen, Peter Lommer ^a   Høi Hansen, Thomas ^a   Boomsma, Frans ^b   Pedersen Bjergaard, Ulrik ^a   Thorsteinsson, Birger ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; DIABETIC PATIENT; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MENTAL PERFORMANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RATING SCALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ALZHEIMER DISEASE; BLOOD GLUCOSE; COGNITION; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HORMONES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RENIN-ANGIOTENSIN SYSTEM; SINGLE-BLIND METHOD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70149118545     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.04.026     Document Type: Article

References (35)

1. Teves D., Videen T.O., Cryer P.E., et al. Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci 101 (2004) 6217-6221
2. Pardridge W.M. Advances in cell biology of blood-brain barrier transport. Semin Cell Biol 2 (1991) 419-426
3. Gruetter R., Novotny E.J., Boulware S.D., et al. Direct measurement of brain glucose concentrations in humans by 13C NMR spectroscopy. Proc Natl Acad Sci 89 (1992) 1109-1112
4. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
5. Sone H., Deo B.K., and Kumagai A.K. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci 41 (2000) 1876-1884
6. Pekala P., Marlow M., Heuvelman D., et al. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 265 (1990) 18051-18054
7. Satake S., Kuzuya M., Miura H., et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Cell 90 (1998) 161-168
8. Dantz D., Bewersdorf J., Fruehwald-Schultes B., et al. Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocrinol Metab 87 (2002) 835-840
9. Merl V., Peters A., Oltmanns K.M., et al. Antecedent hypoglycaemia attenuates vascular endothelial growth factor response to subsequent hypoglycaemia in healthy men. Diabet Med 22 (2005) 1278-1281
10. Oltmanns K.M., Melchert U.H., Scholand-Engler H.G., et al. Divergent effects of hyper- and hypoglycemia on circulating vascular endothelial growth factor in humans. Metabolism 57 (2008) 90-94
11. Peters A., Schweiger U., Fruhwald-Schultes B., et al. The neuroendocrine control of glucose allocation. Exp Clin Endocrinol Diabetes 110 (2002) 199-211
12. Pedersen-Bjergaard U., Thomsen C.E., Hogenhaven H., et al. Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans. J Renin Angiotensin Aldosterone Syst 9 (2008) 37-48
13. Pedersen-Bjergaard U., Agerholm-Larsen B., Pramming S., et al. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 357 (2001) 1248-1253
14. Pedersen-Bjergaard U., Agerholm-Larsen B., Pramming S., et al. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia 46 (2003) 89-96
15. Nordfeldt S., and Samuelsson U. Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes. Diabetes Care 26 (2003) 274-278
16. Zammitt N.N., Geddes J., Warren R.E., et al. Serum angiotensin-converting enzyme and frequency of severe hypoglycaemia in type 1 diabetes: does a relationship exist?. Diabet Med 24 (2007) 1449-1454
17. Pedersen-Bjergaard U., Dhamrait S.S., Sethi A.A., et al. Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes. Am J Med 121 (2008) 246.E1-246.E8
18. Williams B., Baker A.Q., Gallacher B., et al. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25 (1995) 913-917
19. Holst J.J. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 24 (1983) 359-365
20. van der Hoorn F.A., Boomsma F., Man in 't Veld A.J., et al. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 487 (1989) 17-28
21. Derkx F.H., Steunkel C., Schalekamp M.P., et al. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 63 (1986) 1008-1015
22. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., et al. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 95 (1997) 2358-2367
23. Admiraal P.J., Derkx F.H., Danser A.H., et al. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 15 (1990) 44-55
24. Jones A., Dhamrait S.S., Payne J.R., et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 42 (2003) 500-506
25. Deary I.J., Hepburn D.A., MacLeod K.M., et al. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 36 (1993) 771-777
26. Wiig E.H., Nielsen N.P., Minthon L., et al. Parietal lobe activation in rapid, automatized naming by adults. Percept Mot Skills 94 (2002) 1230-1244
27. Wiig E.H., Nielsen N.P., Minthon L., et al. Alzheimer's Quick Test: assessment of parietal function (AQT) (2002), Harcourt/PsychCorp, San Antonio (Tex)
28. Gloddek J., Pagotto U., Paez P.M., et al. Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 160 (1999) 483-490
29. Amiel S.A., Pottinger R.C., Archibald H.R., et al. Effect of antecedent glucose control on cerebral function during hypoglycemia. Diabetes Care 14 (1991) 109-118
30. Maloney J.P., Silliman C.C., Ambruso D.R., et al. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275 (1998) H1054-H1061
31. Webb N.J., Myers C.R., Watson C.J., et al. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 10 (1998) 254-257
32. Trovati M., Anfossi G., Cavalot F., et al. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 35 (1986) 818-825
33. Collier A., Patrick A.W., Hepburn D.A., et al. Leucocyte mobilization and release of neutrophil elastase following acute insulin-induced hypoglycaemia in normal humans. Diabet Med 7 (1990) 506-509
34. Dullaart R.P., Oomen P.H., and Sluiter W.J. Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus. Eur J Intern Med 18 (2007) 193-195
35. In: Strauss E., Sherman M.S., and Spreen O. (Eds). Executive function. In: A compendium of neuropsychological tests (2006), Oxford University Press, Oxford 401-545